Cancer Research

A University of Warwick computer scientist is working with technology that could revolutionise how some cancers are diagnosed.

University contributes to scientific breakthrough for cancer patients

Tests have shown that a new cancer drug, FY26, is 49 times more potent than the clinically used treatment Cisplatin.

A research team from Imperial College Business School has been chosen by the Health Foundation to be part of its £1.5 million Efficiency Research Programme. The award is for original research on system efficiency and value for money in health and social care.

Scientists have discovered a protein that plays a central role in promoting immunity to viruses and cancer, opening the door to new therapies.

A new drug for ovarian cancer, developed by researchers at the University of Cambridge and AstraZeneca, has become the first of new class of drugs, known as PARP-inhibitors, to be granted approval anywhere in the world. The drug, Lynparza, has been granted Marketing Authorisation from the European Commission.

The EU-funded BASTION project aims to build relationships between science and industry and promote the translation of cancer research into new treatments. But a number of obstacles must be removed before true collaboration can flourish